MDMA-PTSD phase 3 evidence

Following highly encouraging results in multiple Phase II trials investigating the use of MDMA to treat PTSD, the first Phase III RCT trial evidence was published in the prestigious journal Nature Medicine in June this year and concluded that MDMA-assisted therapy is highly efficacious in individuals with severe PTSD.

The authors concluded that MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and that the treatment is safe and well-tolerated, even in those with comorbidities and “represents a potential breakthrough treatment that merits expedited clinical evaluation”.

Following the success in this study it is likely that MDMA will become an FDA approved treatment for PTSD in 2023 or 2024. Phase II studies have previously obtained positive results using MDMA for the treatment of PTSD for cohorts including war veterans, first responders, individuals with sexual trauma, amongst others. Read the full article here